14 results
P
patients with neurological disorders
I/C
eslicarbazepine acetate (ESL), placebo
O
tolerability and safety profile
P
patients with lung cancer
I/C
immune checkpoint inhibitors, ?
O
cutaneous toxicity
P
12,501 participants
I/C
topical drugs and device-based therapies, placebo, vehicle, no treatment, or an active topical or device-based treatment
O
complete cure rate, mycological cure rate, adverse events
P
patients prior to blood product transfusions
I/C
anti-allergic agents (e.g. dexamethasone, chlorpheniramine or promethazine), control groups
O
transfusion reactions
P
children with multisystem inflammatory syndrome (MIS-C)
I/C
COVID-19 pandemic
O
clinical manifestations and outcomes of MIS-C associated with COVID-19
P
adults with breast cancer
I/C
immune checkpoint inhibitors (ICIs), other conventional therapies
O
any-grade and grade 3-5 adverse events (AEs) and immune-related AEs (irAEs)
P
children
I/C
ear molding, no intervention
O
success rate
P
ALK-TKIs
I/C
alectinib, criztotinib, brigatinib, ensartinib, ceritinib, lorlatinib, grade 3-4 AEs, fatal AEs, treatment discontinuation due to AEs
O
different toxicity spectra, safest ALK-TKI drug
P
young adults, older adults
I/C
COVID-19 vaccines, young adults vs. older adults
O
GMT values, incidence of local and systemic AEs
P
SLE patients
I/C
cSLE, aSLE
O
clinical manifestations, mortality